RedHill Biopharma Gets 180-Day Nasdaq Extension to Regain $1.00 Bid Price
RDHL is trading near its 52-week low of $0.465 (7.2% above the low).
Summary
Nasdaq granted RedHill Biopharma an additional 180 days, until April 5, 2027, to regain compliance with the $1.00 minimum bid price requirement. The stock trades at $0.4981, and the company faces a going concern warning.
Key Events · Legal and Risk Events · RDHL
-
Nasdaq Extension Granted
Nasdaq granted RedHill an additional 180 calendar days, until April 5, 2027, to regain compliance with the $1.00 minimum bid price requirement.
-
Compliance Deadline Extended
The original deadline of October 5, 2026 was extended after the company failed to regain compliance; the ADS price remains at $0.4981, well below the $1.00 threshold.
-
Going Concern Risk Persists
The extension comes amid a going concern warning disclosed on September 30, 2026, with only $5.3 million in cash and a $6.1 million first-half net loss.
-
Path to Compliance
To regain compliance, the ADS closing bid price must be at least $1.00 for 10 consecutive business days before April 5, 2027; the company may consider a reverse split or other options.
Analysis · RDHL · Life Sciences
RedHill Biopharma received a 180-day extension from Nasdaq, pushing its deadline to regain the $1.00 minimum bid price to April 5, 2027. The stock currently trades at $0.4981, far below the requirement, and the company has a going concern warning with only $5.3 million in cash. The extension removes immediate delisting risk but does not solve the underlying problem — the company must get the ADS price above $1.00 for 10 consecutive business days, likely requiring a reverse split or a sustained rally.
How filings like this one have moved
In the 30 days to Oct 7, 2026, 36.1% of the 1056 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDHL was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $0.46 to $2.16. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.